These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 16951768)
1. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast? Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768 [TBL] [Abstract][Full Text] [Related]
2. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. Engels K; Fox SB; Whitehouse RM; Gatter KC; Harris AL J Pathol; 1997 Aug; 182(4):414-20. PubMed ID: 9306962 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. Lee AH; Dublin EA; Bobrow LG J Pathol; 1999 Feb; 187(3):285-90. PubMed ID: 10398080 [TBL] [Abstract][Full Text] [Related]
4. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast. Vogl G; Dietze O; Hauser-Kronberger C Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200 [TBL] [Abstract][Full Text] [Related]
5. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238 [TBL] [Abstract][Full Text] [Related]
6. Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast. Teo NB; Shoker BS; Jarvis C; Sloane JP; Holcombe C J Clin Pathol; 2003 Dec; 56(12):919-23. PubMed ID: 14645350 [TBL] [Abstract][Full Text] [Related]
7. Comparison of ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma. Kurosumi M; Sugamata N; Tabei T; Inoue K; Matsumoto H; Suemasu K; Higashi Y Anticancer Res; 2002; 22(1A):331-8. PubMed ID: 12017313 [TBL] [Abstract][Full Text] [Related]
8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA Breast J; 2009; 15(2):120-32. PubMed ID: 19292797 [TBL] [Abstract][Full Text] [Related]
11. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076 [TBL] [Abstract][Full Text] [Related]
12. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion. Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252 [TBL] [Abstract][Full Text] [Related]
13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
14. Breast carcinogenesis. Transition from hyperplasia to invasive lesions. Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768 [TBL] [Abstract][Full Text] [Related]
15. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast. Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623 [TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma]. Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093 [TBL] [Abstract][Full Text] [Related]
17. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. Sapino A; Bongiovanni M; Cassoni P; Righi L; Arisio R; Deaglio S; Malavasi F J Pathol; 2001 Jun; 194(2):254-61. PubMed ID: 11400156 [TBL] [Abstract][Full Text] [Related]
18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Park SS; Kim SW Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359 [TBL] [Abstract][Full Text] [Related]
19. Predictors of disease progression in ductal carcinoma in situ of the breast and vascular patterns. Adler EH; Sunkara JL; Patchefsky AS; Koss LG; Oktay MH Hum Pathol; 2012 Apr; 43(4):550-6. PubMed ID: 21925705 [TBL] [Abstract][Full Text] [Related]
20. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast. Tan PH; Chuah KL; Chiang G; Wong CY; Dong F; Bay BH Oncol Rep; 2002; 9(5):1081-6. PubMed ID: 12168077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]